Join
Live feed
·
INSIDERFilingvia Quantisnow
enGene Therapeutics Inc. logo

New insider Boyd Matthew Ross claimed ownership of 7,500 shares (SEC Form 3)

ByQuantisnow·Wall Street's wire, on your screen.
ENGN· enGene Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENGN (enGene Therapeutics Inc.) and more on Quantisnow.